Smear Campaign
Executive Summary
Pap smears, unlike most other high-volume tests, are manual, subjecting them to human error and inexact judgments. To offset these deficiencies, scientists have been working for nearly three decades to develop automated screening systems, endeavors that until recently were littered with failures.
You may also be interested in...
VisionGate Inc.
In early 2001, after leaviing his post as executive chairman of TriPath Imaging, Alan Nelson founded VisionGate Inc., which is focused on developing a test for lung cancer screening. The technology he designed directly measures and quantifies structural changes in chromatin indicative of early-stage lung cancer, and uses proprietary optical microscopy that enables 3-D analysis. The result, he believes, is the first effective clinical screening test for this almost always fatal disease.
VisionGate Inc.
In early 2001, after leaviing his post as executive chairman of TriPath Imaging, Alan Nelson founded VisionGate Inc., which is focused on developing a test for lung cancer screening. The technology he designed directly measures and quantifies structural changes in chromatin indicative of early-stage lung cancer, and uses proprietary optical microscopy that enables 3-D analysis. The result, he believes, is the first effective clinical screening test for this almost always fatal disease.
Exact Sciences' Moment
Exact Sciences and its distribution partner, LabCorp are on the verge of launching a new molecular test for colon cancer screening. They've taken deal-making in diagnostics to a new level, but now they have to deliver on their promises.